Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Pharmaceutical company reports second quarter results
September 5th, 2004
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) announced consolidated financial results for the 3 and 6 months ended June 30, 2004. The company's net loss for the 3 months ended June 30, 2004, was approximately $14,842,000, or $0.28 per diluted share, compared to a net loss of approximately $15,550,000, or $0.30 per diluted share, for the 3 months ended June 30, 2003. Total revenues during the second quarter of 2004 were approximately $673,000, compared to zero for the corresponding period in 2003. This increase in revenues was driven by sales of Plenaxis, the company's first product, which in late 2003 was granted approval by the U.S. Food and...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
